Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.

Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM.

Blood Adv. 2019 Mar 26;3(6):875-883. doi: 10.1182/bloodadvances.2018027599.

2.

Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.

Yucebay F, Matthews C, Puto M, Li J, William B, Jaglowski SM, Penza SL, Vasu S, Benson DM, Andritsos LA, Devine SM, Efebera YA, Roddy JVF.

Leuk Lymphoma. 2019 Feb 15:1-7. doi: 10.1080/10428194.2019.1573996. [Epub ahead of print]

PMID:
30764681
3.

BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.

Singer S, Sharma N, Dean R, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA.

Bone Marrow Transplant. 2019 Feb 4. doi: 10.1038/s41409-019-0463-y. [Epub ahead of print]

PMID:
30718797
4.

BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.

Singer S, Dean R, Zhao Q, Sharma N, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1107-1115. doi: 10.1016/j.bbmt.2019.01.032. Epub 2019 Feb 1.

PMID:
30716453
5.

Identification of the Binding Site of Apical Membrane Antigen 1 (AMA1) Inhibitors Using a Paramagnetic Probe.

Akter M, Drinkwater N, Devine SM, Drew SC, Krishnarjuna B, Debono CO, Wang G, Scanlon MJ, Scammells PJ, McGowan S, MacRaild CA, Norton RS.

ChemMedChem. 2019 Mar 5;14(5):603-612. doi: 10.1002/cmdc.201800802. Epub 2019 Feb 13.

PMID:
30653832
6.

Synthesis and Pharmacological Evaluation of Noscapine-Inspired 5-Substituted Tetrahydroisoquinolines as Cytotoxic Agents.

Devine SM, Yong C, Amenuvegbe D, Aurelio L, Muthiah D, Pouton C, Callaghan R, Capuano B, Scammells PJ.

J Med Chem. 2018 Sep 27;61(18):8444-8456. doi: 10.1021/acs.jmedchem.8b00986. Epub 2018 Sep 14.

PMID:
30156410
7.

A challenge to discriminating psychosocial eligibility criteria: exploring the ethical justification for excluding patients with psychosocial risk factors from hematopoietic cell transplantation.

Richardson DR, Devine SM, Nash R.

Bone Marrow Transplant. 2018 Nov;53(11):1474-1477. doi: 10.1038/s41409-018-0213-6. Epub 2018 Jun 6. No abstract available.

PMID:
29875374
8.

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?

Robinson TM, Fuchs EJ, Zhang MJ, St Martin A, Labopin M, Keesler DA, Blaise D, Bashey A, Bourhis JH, Ciceri F, Ciurea SO, Devine SM, Mohty M, McCurdy SR, Milpied N, McNiece IK, Rocha V, Romee R, Socie G, Yakoub-Agha I, Soiffer RJ, Eapen M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research.

Blood Adv. 2018 Jun 12;2(11):1180-1186. doi: 10.1182/bloodadvances.2018018291.

9.

MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function.

Zitzer NC, Snyder K, Meng X, Taylor PA, Efebera YA, Devine SM, Blazar BR, Garzon R, Ranganathan P.

J Immunol. 2018 Jun 15;200(12):4170-4179. doi: 10.4049/jimmunol.1701465. Epub 2018 May 2.

PMID:
29720426
10.

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.

Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Jones D, Heerema NA, Lozanski G, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, Blum W.

Haematologica. 2018 Jun;103(6):982-987. doi: 10.3324/haematol.2017.186890. Epub 2018 Mar 22.

11.

A Structure-Activity Relationship Study of Bitopic N6-Substituted Adenosine Derivatives as Biased Adenosine A1 Receptor Agonists.

Aurelio L, Baltos JA, Ford L, Nguyen ATN, Jörg M, Devine SM, Valant C, White PJ, Christopoulos A, May LT, Scammells PJ.

J Med Chem. 2018 Mar 8;61(5):2087-2103. doi: 10.1021/acs.jmedchem.8b00047. Epub 2018 Feb 23.

PMID:
29446948
12.

Safety Profile of Good Manufacturing Practice Manufactured Interferon γ-Primed Mesenchymal Stem/Stromal Cells for Clinical Trials.

Guess AJ, Daneault B, Wang R, Bradbury H, La Perle KMD, Fitch J, Hedrick SL, Hamelberg E, Astbury C, White P, Overolt K, Rangarajan H, Abu-Arja R, Devine SM, Otsuru S, Dominici M, O'Donnell L, Horwitz EM.

Stem Cells Transl Med. 2017 Oct;6(10):1868-1879. doi: 10.1002/sctm.16-0485. Epub 2017 Sep 9.

13.

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.

Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL.

Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. Erratum in: Lancet Haematol. 2018 Aug;5(8):e332. Erratum in: Lancet Haematol. 2018 Dec;5(12):e608.

14.

Haploidentical Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide: Does Graft Source Matter?

Devine SM.

J Clin Oncol. 2017 Sep 10;35(26):2984-2986. doi: 10.1200/JCO.2017.73.7775. Epub 2017 Jul 10. No abstract available.

PMID:
28692380
15.

A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.

Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA.

Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):347-353. doi: 10.1016/j.clml.2017.05.008. Epub 2017 May 22.

16.

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.

Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M.

J Hematol Oncol. 2017 Jun 12;10(1):117. doi: 10.1186/s13045-017-0487-y.

17.

Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease.

Chen YB, Perales MA, Li S, Kempner M, Reynolds C, Brown J, Efebera YA, Devine SM, El-Jawahri A, McAfee SL, Spitzer TR, Soiffer RJ, Ritz J, Cutler C.

Blood. 2017 Jun 15;129(24):3256-3261. doi: 10.1182/blood-2017-03-772210. Epub 2017 May 4.

18.

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM.

Blood. 2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3.

19.

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME.

J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.

20.

Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA.

Clin Pharmacol Ther. 2017 Sep;102(3):511-519. doi: 10.1002/cpt.644. Epub 2017 May 26.

21.

Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding.

Ranganathan P, Ngankeu A, Zitzer NC, Leoncini P, Yu X, Casadei L, Challagundla K, Reichenbach DK, Garman S, Ruppert AS, Volinia S, Hofstetter J, Efebera YA, Devine SM, Blazar BR, Fabbri M, Garzon R.

J Immunol. 2017 Mar 15;198(6):2500-2512. doi: 10.4049/jimmunol.1601778. Epub 2017 Feb 3.

22.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD.

Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1.

23.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS.

J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1. No abstract available.

PMID:
28148207
24.

A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.

Haverkos BM, Huang Y, Elder P, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SM.

Bone Marrow Transplant. 2017 Apr;52(4):561-566. doi: 10.1038/bmt.2016.304. Epub 2017 Jan 9.

25.

Antimalarial drug discovery targeting apical membrane antigen 1.

Devine SM, MacRaild CA, Norton RS, Scammells PJ.

Medchemcomm. 2016 Nov 4;8(1):13-20. doi: 10.1039/c6md00495d. eCollection 2017 Jan 1. Review.

26.

How do stem cells mobilize? Bridging the GAP.

Devine SM.

Blood. 2016 Sep 15;128(11):1445-6. doi: 10.1182/blood-2016-07-726414. No abstract available.

27.

Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians.

Wood WA, McGinn MK, Wilson D, Deal AM, Khera N, Shea TC, Devine SM, Appelbaum FR, Horowitz MM, Lee SJ.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2092-2099. doi: 10.1016/j.bbmt.2016.07.014. Epub 2016 Jul 29.

28.

VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model.

Chuo CH, Devine SM, Scammells PJ, Krum H, Christopoulos A, May LT, White PJ, Wang BH.

Clin Exp Pharmacol Physiol. 2016 Oct;43(10):976-82. doi: 10.1111/1440-1681.12616.

PMID:
27377874
29.

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.

Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, Vincent BG, Tkachev V, Pawlicki JM, Furlan SN, Kean LS, Aoyama K, Taylor PA, Panoskaltsis-Mortari A, Foncea R, Ranganathan P, Devine SM, Burrill JS, Guo L, Sacristan C, Snyder NW, Blair IA, Milone MC, Dustin ML, Riley JL, Bernlohr DA, Murphy WJ, Fife BT, Munn DH, Miller JS, Serody JS, Freeman GJ, Sharpe AH, Turka LA, Blazar BR.

J Clin Invest. 2016 Jul 1;126(7):2642-60. doi: 10.1172/JCI85796. Epub 2016 Jun 13.

30.

Erratum to "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease" [Biol Blood Marrow Transplant 22(2016):658-668].

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1341. doi: 10.1016/j.bbmt.2016.03.033. Epub 2016 Apr 29. No abstract available.

31.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.

Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML; Blood and Marrow Transplant Clinical Trials Network.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1440-1448. doi: 10.1016/j.bbmt.2016.04.014. Epub 2016 Apr 23.

32.

Endothelial chimerism in chronic sclerotic-type chronic graft-versus-host disease (GVHD) and GVHD-associated angiomatosis.

Kaffenberger BH, Zhang E, Duncan JR, Jaglowski S, Klisovic RB, Devine SM, Wong HK, Gru AA.

Br J Dermatol. 2016 Oct;175(4):782-4. doi: 10.1111/bjd.14484. Epub 2016 Jun 10.

PMID:
26875995
33.

Solution NMR characterization of apical membrane antigen 1 and small molecule interactions as a basis for designing new antimalarials.

Krishnarjuna B, Lim SS, Devine SM, Debono CO, Lam R, Chandrashekaran IR, Jaipuria G, Yagi H, Atreya HS, Scanlon MJ, MacRaild CA, Scammells PJ, Norton RS.

J Mol Recognit. 2016 Jun;29(6):281-91. doi: 10.1002/jmr.2529. Epub 2016 Jan 24.

PMID:
26804042
34.

Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.

Walker AR, Wang H, Walsh K, Bhatnagar B, Vasu S, Garzon R, Canning R, Geyer S, Wu YZ, Devine SM, Klisovic R, Blum W, Marcucci G.

Leuk Lymphoma. 2016 Sep;57(9):2100-8. doi: 10.3109/10428194.2015.1135435. Epub 2016 Jan 19.

35.

Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM.

Biol Blood Marrow Transplant. 2016 Apr;22(4):658-668. doi: 10.1016/j.bbmt.2015.12.015. Epub 2015 Dec 29. Erratum in: Biol Blood Marrow Transplant. 2016 Jul;22(7):1341.

36.

The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial.

Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V, Devine SM, Waller EK, Jagirdar N, Herrera AF, Cutler C, Ho VT, Koreth J, Alyea EP, McAfee SL, Soiffer RJ, Chen YB, Antin JH.

Br J Haematol. 2016 Apr;173(1):96-104. doi: 10.1111/bjh.13931. Epub 2016 Jan 5.

37.

Plasmacytoid dendritic cells in allogeneic hematopoietic cell transplantation: benefit or burden?

Auletta JJ, Devine SM, Waller EK.

Bone Marrow Transplant. 2016 Mar;51(3):333-43. doi: 10.1038/bmt.2015.301. Epub 2015 Dec 7. Review.

38.

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.

Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP.

J Clin Oncol. 2015 Dec 10;33(35):4167-75. doi: 10.1200/JCO.2015.62.7273. Epub 2015 Nov 2.

39.

Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).

Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM.

Biol Blood Marrow Transplant. 2016 Jan;22(1):71-9. doi: 10.1016/j.bbmt.2015.07.034. Epub 2015 Aug 6.

40.

Tocilizumab for steroid refractory acute graft-versus-host disease.

Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA.

Leuk Lymphoma. 2016;57(1):81-5. doi: 10.3109/10428194.2015.1045896. Epub 2015 Jul 3.

41.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringdén OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M.

Blood. 2015 Aug 20;126(8):1033-40. doi: 10.1182/blood-2015-04-639831. Epub 2015 Jun 30.

42.

Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome.

Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL.

Bone Marrow Transplant. 2015 Aug;50(8):1057-62. doi: 10.1038/bmt.2015.82. Epub 2015 Apr 27.

43.

Design, Synthesis, and Biological Evaluation of Tetra-Substituted Thiophenes as Inhibitors of p38α MAPK.

Vinh NB, Devine SM, Munoz L, Ryan RM, Wang BH, Krum H, Chalmers DK, Simpson JS, Scammells PJ.

ChemistryOpen. 2015 Feb;4(1):56-64. doi: 10.1002/open.201402076. Epub 2014 Nov 11.

44.

Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.

Cohen JB, Ruppert AS, Heerema NA, Andritsos LA, Jones JA, Porcu P, Baiocchi R, Christian BA, Byrd JC, Flynn J, Penza S, Devine SM, Blum KA.

Clin Lymphoma Myeloma Leuk. 2015 May;15(5):278-285.e1. doi: 10.1016/j.clml.2014.12.012. Epub 2014 Dec 31.

PMID:
25660723
45.

Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold.

Devine SM, Mulcair MD, Debono CO, Leung EW, Nissink JW, Lim SS, Chandrashekaran IR, Vazirani M, Mohanty B, Simpson JS, Baell JB, Scammells PJ, Norton RS, Scanlon MJ.

J Med Chem. 2015 Feb 12;58(3):1205-14. doi: 10.1021/jm501402x. Epub 2015 Jan 16.

PMID:
25559643
46.

Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial.

Maziarz RT, Devos T, Bachier CR, Goldstein SC, Leis JF, Devine SM, Meyers G, Gajewski JL, Maertens J, Deans RJ, Van't Hof W, Lazarus HM.

Biol Blood Marrow Transplant. 2015 Apr;21(4):720-8. doi: 10.1016/j.bbmt.2014.12.025. Epub 2014 Dec 30.

47.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD.

JAMA Neurol. 2015 Feb;72(2):159-69. doi: 10.1001/jamaneurol.2014.3780.

48.

Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.

Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, Bunjes DW, Zhang MJ.

Biol Blood Marrow Transplant. 2015 Mar;21(3):454-9. doi: 10.1016/j.bbmt.2014.11.007. Epub 2014 Nov 15.

49.

Improved accuracy of acute graft-versus-host disease staging among multiple centers.

Levine JE, Hogan WJ, Harris AC, Litzow MR, Efebera YA, Devine SM, Reshef R, Ferrara JL.

Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):283-7. doi: 10.1016/j.beha.2014.10.011. Epub 2014 Oct 15. Review.

50.

Health-related quality of life in patients who develop bronchiolitis obliterans syndrome following allo-SCT.

Amin EN, Phillips GS, Elder P, Jaglowski S, Devine SM, Wood KL.

Bone Marrow Transplant. 2015 Feb;50(2):289-95. doi: 10.1038/bmt.2014.264. Epub 2014 Nov 24.

Supplemental Content

Loading ...
Support Center